Tuya (NYSE:TUYA) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $45.02 million which beat the analyst consensus estimate of $44.11 million by 2.05 percent. This is a 47.40 percent decrease over sales of $85.58 million the same period last year.
Hope for Kidney Cancer Patients, Merck’s Keytruda Cuts Risk Of Death By 38% Following Surgery
Results from Merck's Phase 3 KEYNOTE-564 trial. Keytruda, an adjuvant treatment for renal cell carcinoma, shows a 38% improvement in overall survival at 57.2 months.